– CANADA, Toronto – Inagene Diagnostics Inc. today announced the appointment of Nancy White as its Chief Executive Officer.
“We are excited about Nancy’s vision for Inagene,” said Don Wright, Chairman of the Board. “Nancy’s deep expertise in sales and marketing will help Inagene accelerate the commercialization of our organization.”
Nancy joined Inagene in January to help develop the sales and marketing strategy. Now that Inagene’s Personal InsightsTM test has been successfully launched, Nancy’s deep commercial expertise will help Inagene accelerate sales and business development partnerships.
We are also pleased to announce that Peter Brenders has taken on the role of Strategic Advisor to the Chairman of Inagene. In his new capacity, Peter will play a key role in the company’s next stage of development, supporting the Board and senior management as Inagene grows and plans for expansion. Peter was brought on last year to help set the strategic direction and deliver a commercial launch plan. We have been delighted with the company ‘s success in launching not only its first product but also launching our company.
In the shadow of the opioid crisis, unrelieved pain costs Canadians up to $60 billion yearly in health care expenditures and lost productivity.1 Many Canadians struggle to find adequate relief.
“We are committed to ongoing research and want to make a meaningful difference in the lives of patients suffering from pain,” noted Dr. Katherine Siminovitch, FRCP(C), ABIM, Chief Science Advisor, Inagene Diagnostics Inc.
Inagene’s Personalized Insights focuses on providing the most comprehensive genetic test for pain treatments and dependency risk covering 55 genes and 116 variants. Inagene’s own dedicated genetics and research testing lab service is available directly to patients or by recommendation of their healthcare professional.
For more information: https://inagene.com/en/
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.